At baseline, subjects had between 20% to 65% area of target nail involved.
At baseline, subjects were normolipidemic with values of 163.9±41.8, 84.8±36.7, 60.6±15.4 and 93.1±52 mg dl−1 for total cholesterol, LDL cholesterol and HDL cholesterol and triglyceride concentrations, respectively.
The experimental design includes two main treatments and a baseline: in the baseline subjects play a trust game with no networks being formed, in treatment NT the network building phase precedes the trust game, and in treatment TN the network game is played at the end.
At baseline, subjects completed the structured headache intake form.
At baseline, subjects were experiencing 5 migraine days and 6.8 headache days per month on average (Table 2).
RESULTS: At baseline, subjects had an average age of 53.2 yr, had a body mass index of 29.7 kg x m -2), and a relative peak VO2 of 28.7 m -2 kg(-1) x min(-1).
At baseline, subjects with migraine all suffered from headache (Table 2) and had a high headache intensity (VAS = 6.4 ± 2.6) and frequency (4.7 ± 2.4 days) in the past week (Table 3).
At baseline, subjects underwent a physical and neurological examination and a live interview administered via a detailed, semistructured questionnaire on their 1) clinical migraine features; 2) demographics, lifestyle, and behavioural factors; and 3) comorbidities and concomitant medications [20].
At baseline, subjects recorded the amount of any caffeine-containing foods and beverages consumed in the preceding 4 h, administered a single 4-tablet dose of the study medication and then abstained from caffeine-containing foods and beverages for the following 4 h.
